JP2018531961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531961A5 JP2018531961A5 JP2018521382A JP2018521382A JP2018531961A5 JP 2018531961 A5 JP2018531961 A5 JP 2018531961A5 JP 2018521382 A JP2018521382 A JP 2018521382A JP 2018521382 A JP2018521382 A JP 2018521382A JP 2018531961 A5 JP2018531961 A5 JP 2018531961A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stroke
- hours
- onset
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 57
- 208000006011 Stroke Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 19
- 208000028389 Nerve injury Diseases 0.000 claims description 15
- 230000008764 nerve damage Effects 0.000 claims description 15
- 238000011084 recovery Methods 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- 206010014498 Embolic stroke Diseases 0.000 claims description 4
- 206010043647 Thrombotic Stroke Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000037906 ischaemic injury Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246574P | 2015-10-26 | 2015-10-26 | |
| US62/246,574 | 2015-10-26 | ||
| PCT/US2016/058804 WO2017075013A1 (en) | 2015-10-26 | 2016-10-26 | Methods and compositions for recovery from stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531961A JP2018531961A (ja) | 2018-11-01 |
| JP2018531961A5 true JP2018531961A5 (enExample) | 2019-12-05 |
| JP6889493B2 JP6889493B2 (ja) | 2021-06-18 |
Family
ID=58631977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521382A Active JP6889493B2 (ja) | 2015-10-26 | 2016-10-26 | 脳卒中からの回復のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3368040B1 (enExample) |
| JP (1) | JP6889493B2 (enExample) |
| KR (1) | KR102891465B1 (enExample) |
| CN (1) | CN108348524A (enExample) |
| WO (1) | WO2017075013A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| US20220048915A1 (en) * | 2018-11-30 | 2022-02-17 | Shanghai Pharmaceuticals Holding Co., Ltd. | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof |
| JP7384341B1 (ja) | 2023-07-07 | 2023-11-21 | 学校法人冬木学園 | 脳卒中患者の身体の痛みの改善を目的とするリハビリテーションの効果を予測するための方法、及び、システム |
| WO2026128463A1 (en) * | 2024-12-09 | 2026-06-18 | Eip Pharma, Inc. | Neflamapimod for use in methods of treating aphasia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608060B1 (en) | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
| EP1490025B1 (en) * | 2002-03-20 | 2008-02-13 | Elan Pharma International Limited | Nanoparticulate compositions of map kinase inhibitors |
| WO2003084524A1 (en) * | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| EP2296653B1 (en) * | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US9816336B2 (en) | 2014-07-08 | 2017-11-14 | Halliburton Energy Services, Inc. | Real time conformance |
| US9579322B2 (en) * | 2014-07-09 | 2017-02-28 | Eip Pharma, Llc | Methods for treating neurologic disorders |
-
2016
- 2016-10-26 CN CN201680062719.5A patent/CN108348524A/zh active Pending
- 2016-10-26 JP JP2018521382A patent/JP6889493B2/ja active Active
- 2016-10-26 WO PCT/US2016/058804 patent/WO2017075013A1/en not_active Ceased
- 2016-10-26 KR KR1020187012006A patent/KR102891465B1/ko active Active
- 2016-10-26 EP EP16860660.6A patent/EP3368040B1/en active Active